Ariel Jaffe, MD
Assistant Professor of Medicine (Digestive Diseases), Medical Director of Liver Transplant OncologyCards
About
Research
Publications
2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-Novel updates in the field of HCC
Jaffe A, Strazzabosco M. Novel updates in the field of HCC. Clinical Liver Disease 2024, 23: e0142. PMCID: PMC11078519, DOI: 10.1097/cld.0000000000000142.Peer-Reviewed Original ResearchApproach to immunotherapy for HCC in the liver transplant population
Block P, Strazzabosco M, Jaffe A. Approach to immunotherapy for HCC in the liver transplant population. Clinical Liver Disease 2024, 23: e0158. PMID: 38707244, PMCID: PMC11068135, DOI: 10.1097/cld.0000000000000158.Peer-Reviewed Original ResearchArtificial intelligence in liver cancer — new tools for research and patient management
Calderaro J, Žigutytė L, Truhn D, Jaffe A, Kather J. Artificial intelligence in liver cancer — new tools for research and patient management. Nature Reviews Gastroenterology & Hepatology 2024, 21: 585-599. PMID: 38627537, DOI: 10.1038/s41575-024-00919-y.Peer-Reviewed Original ResearchLiver cancer managementLiver cancerCancer managementCancer careArtificial intelligenceClinically approved productsInterdisciplinary trainingTumor typesClinical dataClinical trialsPatient managementClinical useCancerPotential of AILiverHidden informationNatural languageIncorporation of AIAI approachesAI systemsPatientsAutomated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
Gross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 1-13. PMID: 38536464, DOI: 10.1007/s00330-024-10624-8.Peer-Reviewed Original ResearchContrast-enhanced magnetic resonance imagingMagnetic resonance imagingClinical staging systemTime of diagnosisHepatocellular carcinomaClinical dataMortality risk predictionOverall survivalStaging systemRadiomic featuresManagement of hepatocellular carcinomaPersonalized follow-up strategiesAssociated with OSMethodsThis retrospective studyHepatocellular carcinoma patientsBaseline magnetic resonance imagingMRI radiomics featuresIndependent validation cohortHarrell's C-indexRisk predictionFollow-up strategiesHigh-risk groupPredictive risk scoreRadiomics feature extractionMedian timeAutomated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics
Gross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 34: 5056-5065. PMID: 38217704, PMCID: PMC11245591, DOI: 10.1007/s00330-023-10495-5.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiomics feature extractionLiver volumetryIntraclass correlation coefficientRadiomic featuresLiver segmentationAutomated liver volumetryHepatocellular carcinoma patientsMann-Whitney U testAutomated liver segmentationManual segmentationQuantitative imaging biomarkersCarcinoma patientsRetrospective studyInstitutional databaseAnatomical localizationClinical relevanceManual volumetryMann-WhitneyU testExternal validationInternal test setImaging biomarkersInclusion criteriaResultsIn total
2023
Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.
Mezzacappa C, Rossi R, Jaffe A, Taddei T, Strazzabosco M. Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study. Cancer Epidemiology Biomarkers & Prevention 2023, 33: 270-278. PMID: 38059831, PMCID: PMC10872555, DOI: 10.1158/1055-9965.epi-23-0902.Peer-Reviewed Original ResearchAdvancing diagnosis and management of liver disease in adults through exome sequencing
Zheng M, Hakim A, Konkwo C, Deaton A, Ward L, Genetics A, Silveira M, Assis D, Liapakis A, Jaffe A, Jiang Z, Curry M, Lai M, Cho M, Dykas D, Bale A, Mistry P, Vilarinho S. Advancing diagnosis and management of liver disease in adults through exome sequencing. EBioMedicine 2023, 95: 104747. PMID: 37566928, PMCID: PMC10433007, DOI: 10.1016/j.ebiom.2023.104747.Peer-Reviewed Original ResearchConceptsLiver diseaseWhole-exome sequencingUnknown etiologyTertiary referral academic medical centerReferral academic medical centerExome sequencingLiver disease patientsManagement of adultsAcademic health care centerComprehensive clinical evaluationHealth care centersAcademic medical centerGenetic variantsRare genetic variantsAdult patientsLiver centersHepatic steatosisDisease patientsClinical evaluationCare centerFamily historyMedical CenterClinical valueAdult medicinePatientsAdherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma
Cao Y, Mezzacappa C, Jaffe A, Strazzabosco M, Taddei T. Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma. Journal Of Multidisciplinary Healthcare 2023, 16: 1531-1540. PMID: 37283950, PMCID: PMC10239642, DOI: 10.2147/jmdh.s407908.Peer-Reviewed Original ResearchMultidisciplinary liver tumor boardBarcelona Clinic Liver CancerHepatocellular carcinomaBCLC stageLocoregional therapyTreatment-naïve hepatocellular carcinomaTreatment of HCCTumor board recommendationsRetrospective cohort studyTertiary care centerChronic liver diseaseMultivariate Cox regressionKaplan-Meier analysisManagement of patientsTreatment of patientsUnifocal hepatocellular carcinomaCases of discordanceBCLC guidelinesPalliative intentTreatment discordanceUnifocal diseaseChart reviewCohort studyCurative therapyCurative treatmentReply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes?
Torres M, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini E. Reply: Novel antidiabetic drugs and the risk for HCC. What else to expect from these “wonderful” drug classes? Hepatology 2023, 77: e184-e185. PMID: 36724446, DOI: 10.1097/hep.0000000000000312.Commentaries, Editorials and Letters
Academic Achievements & Community Involvement
Clinical Care
Overview
Ariel Jaffe, MD, is a board certified internist, gastroenterologist, and hepatologist who specializes in taking care of patients with advanced liver disease and liver cancer, many of whom are candidates for liver transplants.
“It’s an amazing thing to take care of people when they are at their most vulnerable,” Dr. Jaffe says. “If we can get them to transplant and give them a second chance at life, that’s very rewarding. If transplant is not an option, there are ways we can optimize their care and quality of life, making them as comfortable and as safe as possible.”
Dr. Jaffe says she was drawn to hepatology because of the complexities of liver disease. “Often patients with advanced liver disease have multiple medical problems involving a variety of organs, and I like the challenge of managing that and maintaining expertise in general internal medicine,” she says. “Another reason I love my field is that it requires multidisciplinary input and I am constantly working with colleagues in various departments including interventional radiology, oncology, and surgery, to name a few. It’s an extremely collaborative field and I love that aspect of it.”
Dr. Jaffe’s research is focused on outcomes for liver cancer. “It’s such an exciting time in our field. In the last few years we have not only seen a big change in the landscape of liver disease, but we have also developed many new medical therapies and have learned a lot about how to better treat our patients,” she says. “I hope with the ongoing efforts of my work that we will continue to improve care and become the leading center for treatment of liver disease and liver cancer.”
Clinical Specialties
Fact Sheets
Polycystic Kidney Disease (PKD)
Learn More on Yale MedicineLiver Cancer
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineCirrhosis
Learn More on Yale Medicine
Board Certifications
Transplant Hepatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2022
Gastroenterology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2020
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2017
Yale Medicine News
News & Links
News
- June 21, 2024Source: NewsBreak
5 Things the LGBTQ+ Community Need To Know about Cancer Prevention, Finding the Right Doctor and Overcoming Shame
- February 23, 2024
Department of Internal Medicine Promotions and Appointments (February 2024)
- December 05, 2023
Smilow Shares with Primary Care: Liver Cancer
- February 15, 2023
Discoveries & Impact (February 2023)